


WOODHEAD PUBLISHING SERIES IN BIOMEDICINE

POLYMERS AND NANOMATERIALS FOR GENE THERAPY

EDITED BY RAVIN NARAIN



WP
WOODHEAD
PUBLISHING

Polymers and Nanomaterials for Gene Therapy

This page intentionally left blank

Woodhead Publishing Series in Biomedicine:
Number 83

Polymers and Nanomaterials for Gene Therapy

Edited by

Ravin Narain



ELSEVIER

AMSTERDAM • BOSTON • CAMBRIDGE • HEIDELBERG
LONDON • NEW YORK • OXFORD • PARIS • SAN DIEGO
SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO

Woodhead Publishing is an imprint of Elsevier



Woodhead Publishing is an imprint of Elsevier
80 High Street, Sawston, Cambridge, CB22 3HJ, UK
50 Hampshire Street, 5th Floor, Cambridge, MA 02139, USA
Langford Lane, Kidlington, OX5 1GB, UK

© 2016 Elsevier Ltd. All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions.

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

Notices

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

ISBN: 978-0-08-100520-0 (print)

ISBN: 978-0-08-100521-7 (online)

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library

Library of Congress Control Number: 2015941475

For information on all Woodhead Publishing publications
visit our website at <http://store.elsevier.com/>



Working together
to grow libraries in
developing countries

www.elsevier.com • www.bookaid.org

Contents

List of Contributors	ix
Editor and Author	xi
Contributing Authors	xiii
Preface	xxi
1 Mechanism, current challenges and new approaches for non viral gene delivery	1
<i>B. Thapa, R. Narain</i>	
1.1 Introduction	1
1.2 Current non-viral gene delivery vectors	2
1.3 Trajectory and mechanism of non-viral vectors	9
1.4 Conclusion and future perspective	20
References	20
2 PEI and its derivatives for gene therapy	29
<i>K.C. Remant Bahadur, H. Uludağ</i>	
Abbreviations	29
2.1 Introduction	30
2.2 Criteria for non-viral vectors and general considerations	31
2.3 Rationale for the use of PEI for gene therapy	32
2.4 PEI Derivatives for gene delivery	33
2.5 PEGylation of PEI	41
2.6 Polyester conjugation on PEI	42
2.7 Chitosan conjugation on PEI	42
2.8 PLL conjugation on PEI	43
2.9 Metallic nanoparticles with PEIs	44
2.10 Pharmacokinetics and bio-distribution of PEI delivery vectors	44
2.11 Concluding remarks	45
Acknowledgements	46
References	46
3 Natural polymers in nucleic acid delivery	55
<i>H. Montazeri Aliabadi</i>	
3.1 Introducing cells to exogenous nucleic acids	55
3.2 Delivering nucleic acids to target cells	59
3.3 Polymers as nucleic acid carriers	62
3.4 Conclusion	71
References	71

4	Synthetic cationic glycopolymers for gene delivery	81
	<i>M. Ahmed, R. Narain</i>	
4.1	Introduction	81
4.2	Evaluation of glycosylated cationic polymers for gene delivery	81
4.3	Evaluation of cationic glycopolymers for gene delivery	84
4.4	Role of hydrogen bonding between glycopolymers and DNA	86
4.5	Degradable cationic glycopolymers	93
4.6	Future perspective	95
	References	96
5	Engineering peptide-conjugated non-viral delivery systems for enhanced siRNA and DNA therapeutics	99
	<i>S. Quan, P. Kumar, R. Narain</i>	
5.1	Introduction	99
5.2	Lysine-based peptides	99
5.3	Histidine-based peptides	103
5.4	Arginine-based peptides	104
5.5	Cell-penetrating and fusogenic peptides	107
5.6	Conclusion and future prospects	110
	References	110
6	Dendrimers for gene therapy	113
	<i>M.J. Santander-Ortega, M.V. Lozano, I.F. Uchegbu, A.G. Schätzlein</i>	
6.1	Introduction	113
6.2	Dendrimer structure and chemistry	114
6.3	Dendrimer architecture	117
6.4	Dendrimer generation	118
6.5	Chemical modifications	120
6.6	Dendriplexes formulation	124
6.7	<i>In vitro</i> interaction with cells	126
6.8	<i>In vivo</i> administration	130
6.9	Efficaciousness after <i>in vivo</i> administration	132
6.10	Conclusions	135
	References	136
7	Polymeric nanoparticles for gene delivery	147
	<i>T. Werfel, C. Duvall</i>	
7.1	Introduction	147
7.2	Micelles	148
7.3	Cross-linked micelles	156
7.4	Polymersomes	161
7.5	Microgels/nanogels	166
7.6	Microgels	168
7.7	Nanogels	171
7.8	Outlook	176
	References	180

8	Gold nanomaterials for gene therapy	189
	<i>M. Ebara, K. Uto</i>	
8.1	Introduction	189
8.2	Synthesis of gold nanoparticles	190
8.3	Intracellular uptake of gold nanoparticles	195
8.4	Gene delivery applications	202
8.5	Summary	209
	References	210
9	Fabrication and development of magnetic particles for gene therapy	215
	<i>S. Uthaman, M. Muthiah, I.-K. Park, C.-S. Cho</i>	
9.1	Introduction	215
9.2	Synthesis of magnetic nanoparticles	216
9.3	Surface modification of magnetic particles by polymers	218
9.4	Magnetic particles for gene therapy	220
9.5	Conclusions and future perspectives	223
	References	224
10	Gene therapies in clinical trials	231
	<i>K.I. Papadopoulos, P. Wattanaarsakit, W. Prasongchean, R. Narain</i>	
10.1	Introduction	231
10.2	Gene therapy	231
10.3	Gene replacement/augmentation	232
10.4	Gene Addition	237
10.5	Gene Editing	240
10.6	Short RNA or DNA-based gene expression modulation	242
10.7	Combination approaches	244
	References	247
11	Biochemical assays used for <i>in vitro</i> and <i>in vivo</i> gene expression	257
	<i>M. Ahmed, R. Narain</i>	
11.1	Introduction	257
11.2	Reporter gene assay system	258
11.3	Electrophoretic techniques	262
11.4	Hybridization techniques	264
11.5	Conclusion	268
	References	268
	Index	271

This page intentionally left blank

List of Contributors

M. Ahmed California Institute of Technology, Pasadena, CA, USA

H. Montazeri Aliabadi Chapman University School of Pharmacy, Irvine, CA, USA

C.-S. Cho Department of Agricultural Biotechnology and Research Institute for Agriculture and Life Sciences, Seoul National University, Seoul Republic of Korea

C. Duvall Vanderbilt University, Nashville, TN, USA

M. Ebara National Institute for Materials Science (NIMS), Tsukuba, Japan

P. Kumar University of Alberta, Edmonton, AB, Canada

M.V. Lozano University College of London, London, UK

M. Muthiah Department of Biomedical Science and BK21 PLUS Center for Creative Biomedical Scientists, Chonnam National University Medical School, Republic of Korea

R. Narain University of Alberta, Edmonton, AB, Canada

I.-K. Park Department of Biomedical Science and BK21 PLUS Center for Creative Biomedical Scientists, Chonnam National University Medical School, Republic of Korea

K.I. Papadopoulos THAI StemLife, Bangkok, Thailand

W. Prasongchean Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand

S. Quan University of Alberta, Edmonton, AB, Canada

K.C. Remant Bahadur University of Alberta, Edmonton, AB, Canada

M.J. Santander-Ortega University College of London, London, UK

A.G. Schätzlein University College of London, London, UK

B. Thapa University of Alberta, Edmonton, AB, Canada

I.F. Uchegbu University College of London, London, UK

H. Uludağ University of Alberta, Edmonton, AB, Canada

K. Uto National Institute for Materials Science (NIMS), Tsukuba, Japan

S. Uthaman Department of Biomedical Science and BK21 PLUS Center for Creative Biomedical Scientists, Chonnam National University Medical School, Republic of Korea

P. Wattanaarsakit Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand

T. Werfel Vanderbilt University, Nashville, TN, USA

Editor and Author

Ravin NARAIN, PhD/PEng, is Professor in the Department of Chemical and Materials Engineering at the University of Alberta. He has published more than 120 articles in peer-reviewed journals and is the editor of three books namely Engineered Carbohydrate-Based Materials for Biomedical Applications (Wiley & Sons), Chemistry of Bioconjugates (Wiley & Sons) and Glycopolymers: Synthesis and Applications (Smithers & Rapra). He has also contributed more than 20 chapters in several books. Dr. Narain's research examines nanomedicine and regenerative medicine, with an emphasis on developing new carbohydrate based biomaterials for drug and gene delivery for cancer therapy. In addition, he has an interest in interdisciplinary research and has extensive experience in developing innovative polymers, nanoparticles, and nanofibers for advanced engineering applications. Before joining the University of Alberta in 2009, he held academic appointment (Assistant and Associate Professor) at Laurentian University for the period of 2004–2009. Dr. Narain completed his B.Sc and PhD from the University of Mauritius and he was then appointed as a postdoctoral fellow at University of Sussex, UK (2001–2003) and as a senior research fellow at the University of Washington, U.S.A (2003–2004).

This page intentionally left blank

Contributing Authors

Bindu Thapa

Bindu Thapa is a PhD student at faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Canada. She acquired her Masters degree in Pharmaceutical Sciences from The School of Pharmaceutical and Biomedical Sciences, Pokhara University, Nepal. She worked at Department of Drug discovery and Biomedical Sciences, University of South Carolina, U.S., where she explored interdisciplinary research at the interface of engineering and biology particularly focusing on polymeric drug and gene delivery. Her research interest is exploring non-viral gene delivery systems for transgene expression and cancer therapy based on siRNA delivery.

Hamidreza Montazeri Aliabadi, PhD

Dr. Montazeri graduated with a Pharm.D. degree from Tehran University in 1988. He worked in industrial pharmacy for more than 10 years in different capacities (including research and development, formulation, and quality control), before continuing his studies. He received his PhD in pharmaceutics (working on a project on targeted delivery of small molecule drugs to solid tumors) from the University of Alberta (U of A), in 2007. Shortly after graduation, he was awarded a postdoctoral fellowship by Alberta Heritage Foundation for Medical Research (now known as Alberta Innovates Health Solutions) on a project to design a polymeric carrier for siRNA delivery. After completion of the fellowship in the Department of Chemical and Material Engineering, U of A, Dr. Montazeri wrote a research proposal (in collaboration) for the study of signaling pathways to overcome resistance to chemotherapy in breast cancer, which was awarded a 3-year grant from the Canadian Breast Cancer Foundation. He has authored more than 30 peer-reviewed publications and two previous book chapters as well as 27 meeting abstracts. He is currently an assistant professor of Pharmaceutics in Chapman University in California.

Hasan Uludağ, PhD

Dr. Hasan Uludağ has been with the University of Alberta (Edmonton, Canada) since 1997, currently based at the Department of Chemical & Materials Engineering. He holds joint appoints with the Faculty of Medicine & Dentistry and Faculty of Pharmacy & Pharmaceutical Sciences. Dr. Uludağ is directing interdisciplinary research programs on experimental therapeutics, specifically focusing of designing functional biomaterials to

realize the potential of new, unconventional therapeutic agents. His research activity is conducted in the context of bone regeneration and anti-cancer therapies. Dr. Uludağ is actively involved in various biomaterials societies around the world and is an elected Fellow of the International Union of Society of Biomaterials Science and Engineering (IUS-BSE). Besides acting as the lead editor for *Frontiers in Biomaterials*, he is serving on the editorial board of six international journals. Dr. Uludağ has published >150 peer-reviewed journal articles. He obtained dual B.Sc. degrees in Biomedical Engineering and Biology from Brown University (Providence, RI) in 1989, specializing in biomedical engineering with a strong emphasis in biological sciences. He then completed his PhD degree in 1993 at the Department of Chemical Engineering & Applied Chemistry at the University of Toronto, where he developed a strong expertise in polymeric biomaterials. He spent 4 years in an industrial setting (Genetics Institute Inc., Boston, MA), where he contributed to development of a tissue engineered bone-inducing device for clinical use.

Remant Bahadur, KC

Remant Bahadur, KC is working as a research associate at the Department of Chemical & Materials Engineering, University of Alberta. His research interest includes the design of novel biomaterials to develop drug/gene carriers for cancer therapy. He has been working in interdisciplinary research at the interface of science, engineering and biology for 15 years as a principle and co-investigator. He received a master's degree in organic chemistry (M.Sc.) from Tribhuvan University, Nepal and a PhD in Bionanosystem Engineering from Chonbuk National University, South Korea (2004–2007). He has developed a strong foundation in designing polymeric material of variable architectures during his PhD. Currently, his research is focused on the synthesis of cationic lipo-polymers for cancer gene and cell therapy.

Mitsuhiro Ebara, PhD

Mitsuhiro Ebara is a senior scientist at World Premier International (WPI) Research Centre for Materials Nanoarchitectonics (MANA), the National Institute for Materials Science (NIMS), Japan. He received his PhD degree from Waseda University. His research interests focus on developing “smart” biotechnologies using stimuli-responsive polymers.

Koichiro Uto, PhD

Koichiro Uto is a senior fellow at the Department of Bioengineering, University of Washington in the United States. He received his PhD (Engineering) from Kagoshima University in 2010. He became a postdoctoral fellow at the National Institute for Materials Science (NIMS). His research interests include preparation of “smart” polymers for biomedical applications.